Latest News

This is a summary of the multisystem effects of hidradenitis suppurativa followed by practical tips for primary care in recognizing and managing the chronic skin condition.

Your daily dose of the clinical news you may have missed.

The VITESSE trial met its primary endpoint, with the VIASKIN Peanut patch improving desensitization versus placebo in peanut-allergic children aged 4 to 7 years.

Physician researcher Fendrick offers an expert perspective on why removing cost barriers matters, and why navigation and patient realities still determine whether CRC screening succeeds.

CDC officials say the shift reflects evidence review and informed consent, as public health groups warn of potential downstream effects.

Phase 2b REZOLVE-AA trial results show rezpegaldesleukin reduced SALT scores versus placebo in severe alopecia areata, supporting Phase 3 development.

Approval of the novel long-acting mAb was based on the phase 3 SWIFT-1 and SWIFT-2 trials, which showed steep reductions in annualized asthma exacerbations requiring ED or inpatient care.

This is a topline look for primary care on when to suspect hidradenitis suppurativa, how to stage severity, and when to escalate treatment or refer to dermatology.